Clinical Trials Logo

Lymphoma, T-Cell clinical trials

View clinical trials related to Lymphoma, T-Cell.

Filter by:

NCT ID: NCT01787409 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Start date: March 6, 2013
Phase: N/A
Study type: Interventional

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

NCT ID: NCT01667302 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma.

NCT ID: NCT01664975 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Treatment of Peripheral T-cell Lymphoma

Start date: August 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabine,cisplatin,Prednisone ,Thalidomide ) for patients with Peripheral T-cell lymphoma.

NCT ID: NCT01501149 Recruiting - Clinical trials for Nasal and Nasal-type NK/T-cell Lymphoma

Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ

CTTNKTL-?/?
Start date: January 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine,pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.

NCT ID: NCT01501136 Recruiting - Clinical trials for Nasal and Nasal-type NK/T-cell Lymphoma

Treatment of Natural Killer/T Cell Lymphoma-I/II

CTTNKTL-I/II
Start date: January 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine,pegaspargase,cisplatin,dexamethasone) for patients with newly diagnosed stage I/II Natural Killer (NK)/T Cell Lymphoma.

NCT ID: NCT01470066 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas

Start date: August 2004
Phase: N/A
Study type: Observational

Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computerized tomography (CT) scan has emerged as a powerful prognostic tool in predicting treatment outcome in Hodgkin's lymphoma (HL) and diffuse large B cell lymphoma (DLBCL), the positive predictive value (PPV) of interim PET/CT scanning has not been determined in patients with peripheral T cell lymphoma (PTCL). The sequential interim PET/CT will be prospectively investigated to determine whether it provided additional prognostic information and could be a positive predictable value for the treatment of PTCL.

NCT ID: NCT01132989 Recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

REvMM2009
Start date: May 2010
Phase: Phase 2
Study type: Interventional

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal for the use of Lenalidomide as an adjuvant treatment in patients with refractory cutaneous T cell lymphoma is to increase response rates, maintain a durable long-term response, relieve associated symptoms, and minimize toxic side effects.

NCT ID: NCT01087333 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Start date: March 2, 2010
Phase:
Study type: Observational

Background: - Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell. Objectives: - To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia. Eligibility: - Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers. Design: - Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples. - No treatment will be given as part of this protocol.

NCT ID: NCT00974324 Recruiting - T Cell Lymphoma Clinical Trials

Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma

PTCL
Start date: August 2009
Phase: Phase 2
Study type: Interventional

The role of angiogenesis has been less clear in lymphoma than in solid tumors, in part related to the heterogeneity of disease and technical issues. In addition to vascular endothelial growth factor (VEGF) effects on angiogenesis and the integrity of tumor vasculature, autocrine VEGF-receptor (VEGF-R)-mediated signaling may play a role in lymphoma. Microvessel density, a measure of angiogenesis, is highest in peripheral T-cell lymphomas (PTCL), followed by diffuse large B-cell (DLBCL) and intra-follicular follicular lymphoma (FL).

NCT ID: NCT00933673 Recruiting - Lymphoma Clinical Trials

New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of L-asparaginase plus DICE regimen in the patients with early stage NK/T-cell lymphoma.